JP2019504865A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504865A5 JP2019504865A5 JP2018542754A JP2018542754A JP2019504865A5 JP 2019504865 A5 JP2019504865 A5 JP 2019504865A5 JP 2018542754 A JP2018542754 A JP 2018542754A JP 2018542754 A JP2018542754 A JP 2018542754A JP 2019504865 A5 JP2019504865 A5 JP 2019504865A5
- Authority
- JP
- Japan
- Prior art keywords
- ethanol
- room temperature
- solution
- dihydrophthalazine
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- HWYHZTIRURJOHG-UHFFFAOYSA-N Luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 claims 3
- 238000001035 drying Methods 0.000 claims 3
- 238000001816 cooling Methods 0.000 claims 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims 2
- 238000010992 reflux Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Claims (5)
- 5−アミノ−2,3−ジヒドロフタラジン−1,4−ジオンの結晶形の製造方法であって、
以下の工程:
a)5−アミノ−2,3−ジヒドロフタラジン−1,4−ジオンを、50〜100℃で5:1〜1:1(v/v)の範囲のエタノール−水還流溶液に溶解する工程、
b)前記溶液を60〜240分間かけて室温に冷却する工程、
c)沈殿した結晶生成物を分離する工程、
d)前記結晶生成物を室温で6〜48時間かけて乾燥させる工程、
を含み、
得られた結晶形が、粉末X線回折によって決定された以下の結晶学値:
d値:11.4;11.2;6.9;6.8;6.4;5.6;3.6;3.5;3.5;3.3;3.2および
2θ値:7.8;7.9;12.8;13.0;13.9;15.7;24.9;25.7;25.7;27.2;27.5
によって特徴付けられる
方法。 - 前記得られた結晶形が0.4%以下の結晶含水量を有する、
請求項1に記載の方法。 - 前記エタノールが98%以上の純度を有する、
請求項1又は2に記載の方法。 - 請求項1から3のいずれか1項に記載の方法であって,
e)前記d)工程の後に、得られた結晶形をエタノール中に1〜3回再懸濁し、撹拌し、エタノールで再洗浄し、再び乾燥させる工程をさらに含む方法。 - 前記a)〜d)の工程が、それぞれ:
a)5−アミノ−2,3−ジヒドロフタラジン−1,4−ジオンをエタノール−水還流溶液(3:1、v/v)に80℃で溶解する工程、
b)前記溶液を120分間かけて室温に冷却する工程、
c)沈殿した結晶生成物を分離する工程、および
d)前記結晶生成物を室温で12時間乾燥させる工程である、
請求項1から4のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16000380.2 | 2016-02-16 | ||
EP16000380 | 2016-02-16 | ||
PCT/EP2017/000209 WO2017140422A1 (en) | 2016-02-16 | 2017-02-15 | Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019504865A JP2019504865A (ja) | 2019-02-21 |
JP2019504865A5 true JP2019504865A5 (ja) | 2020-03-26 |
JP6949856B2 JP6949856B2 (ja) | 2021-10-13 |
Family
ID=55361317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018542754A Active JP6949856B2 (ja) | 2016-02-16 | 2017-02-15 | 5−アミノ−2,3−ジヒドロフタラジン−1,4−ジオンの結晶形の製造方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11203575B2 (ja) |
EP (1) | EP3416952B1 (ja) |
JP (1) | JP6949856B2 (ja) |
KR (1) | KR102535959B1 (ja) |
CN (1) | CN109071461B (ja) |
CA (1) | CA3011766C (ja) |
ES (1) | ES2796476T3 (ja) |
WO (1) | WO2017140422A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3511325A1 (en) * | 2018-01-11 | 2019-07-17 | MetrioPharm AG | Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione |
US20210379063A1 (en) * | 2018-10-26 | 2021-12-09 | Immunopharma Plus D.O.O. | Oral aminodihydrophthalazinedione compositions and their use in the treatment of non-viral hepatitis |
KR20220158030A (ko) * | 2020-03-25 | 2022-11-29 | 메트리오팜 아게 | 급성 폐손상 치료용 5-아미노-2,3-디히드로-1,4-프탈라진디온 |
IL298899A (en) * | 2020-06-10 | 2023-02-01 | Metriopharm Ag | A compound for the treatment of corona virus infections |
CA3202852A1 (en) * | 2020-12-01 | 2022-06-09 | Reverspah Llc | Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis and pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, a cute respiratory distress syndrome, and pulmonary arterial hypertension |
WO2022117221A1 (en) * | 2020-12-02 | 2022-06-09 | Metriopharm Ag | Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4743541A (en) * | 1985-07-17 | 1988-05-10 | Mast Immunosystems, Inc. | Luminescent substrate preparation and its use in specific binding assays |
FR2839155B1 (fr) * | 2002-04-25 | 2005-02-04 | Roc Imp | Procede pour detecter et localiser des traces de sang et compose pour detecter des traces de sang |
BRPI0307864B1 (pt) * | 2003-11-25 | 2016-01-12 | Univ Rio De Janeiro | processo para formação de hidrazidas a partir de hidrazinas e ácido dicarboxílicos |
CN100390152C (zh) * | 2006-03-23 | 2008-05-28 | 潘健 | 一种合成3-硝基或3-氨基邻苯二甲酰肼的方法 |
PL231885B1 (pl) * | 2009-01-16 | 2019-04-30 | Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia | Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie |
CH704794B1 (de) * | 2010-03-01 | 2013-04-15 | Metriopharm Ag | Kristalline Form zu 5-Amino-2,3-dihydrophthalazin-1,4-dion Natriumsalz, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung. |
WO2011123776A2 (en) * | 2010-04-01 | 2011-10-06 | Guthery B Eugene | Method for detecting occult blood |
US20110246075A1 (en) * | 2010-04-01 | 2011-10-06 | Banik Niranjan C | Providing a Transform Function to Produce a Mechanical Property of a Subterranean Structure |
-
2017
- 2017-02-15 KR KR1020187026714A patent/KR102535959B1/ko active IP Right Grant
- 2017-02-15 US US15/999,050 patent/US11203575B2/en active Active
- 2017-02-15 WO PCT/EP2017/000209 patent/WO2017140422A1/en active Application Filing
- 2017-02-15 EP EP17711562.3A patent/EP3416952B1/en active Active
- 2017-02-15 JP JP2018542754A patent/JP6949856B2/ja active Active
- 2017-02-15 CA CA3011766A patent/CA3011766C/en active Active
- 2017-02-15 ES ES17711562T patent/ES2796476T3/es active Active
- 2017-02-15 CN CN201780023173.7A patent/CN109071461B/zh active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019504865A5 (ja) | ||
JP2018024682A5 (ja) | ||
JP2018035160A5 (ja) | ||
JP2017222697A5 (ja) | ||
JP2015063536A5 (ja) | ||
JP2014221842A5 (ja) | ||
JP2015044837A5 (ja) | ||
JP2009120624A5 (ja) | ||
JP2010533203A5 (ja) | ||
JP2018505199A5 (ja) | ||
JP2019504103A5 (ja) | ||
JP2011513485A5 (ja) | ||
JP2019505533A5 (ja) | ||
JP2009531465A5 (ja) | ||
JP2019505532A5 (ja) | ||
JP2012500819A5 (ja) | ||
JP2018538331A5 (ja) | ||
JP2018522945A5 (ja) | ||
RU2016118796A (ru) | Новая кристаллическая форма 2-{ 3-[2-(1-{ [3, 5-бис(дифторметил)-1н-пиразол-1-ил]ацетил} пиперидин-4-ил)-1, 3-тиазол-4-ил]-4, 5-дигидро-1, 2-оксазол-5-ил} -3-хлорфенилметансульфоната | |
JP2017210488A5 (ja) | ||
JP2009540007A5 (ja) | ||
JP2013528668A5 (ja) | ||
AR081267A1 (es) | Procedimiento de obtencion de la forma cristalina a del febuxostat | |
JP2018502165A5 (ja) | ||
JP2015515271A5 (ja) |